Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Sep 2, 2010

Premium

Title: Methods and Compositions for Treating and Preventing Neurologic Disorders

Patent Number: 7,786,090

Filed: March 1, 2007

Lead Inventor: Azad Bonni, Harvard University

The intention, the patent's abstract states, "provides methods for treating or reducing neurologic disorders."

It specifically claims the use of interfering RNA to down-regulate human prolyl isomerase Pin 1.


Title: Composition and Method of RNAi Therapeutics for Treatment of Cancer and Other Neovascularization Diseases

Patent Number: 7,786,092

Filed: April 9, 2009

Lead Inventor: Yijia Liu, Intradigm (Silence Therapeutics)

The patent, its abstract states, claims "compositions and methods … for treatment of diseases involving unwanted neovascularization. The invention provides treatments that control [neovascularization] through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological [neovascularization] tissues.

"Tissue-targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference are provided," the abstract adds. "The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of [neovascularization] diseases such as cancer, ocular disease, arthritis, and inflammatory diseases."


Title: Double-Stranded Ribonucleic Acid with Increased Effectiveness in an Organism

Patent Number: 7,786,290

Filed: June 14, 2004 PCT Filed: June 14, 2004

Lead Inventor: Claudia Woppman, Alnylam Pharmaceuticals

The invention relates to "a method for the targeted selection of a double-stranded ribonucleic acid consisting of two single strands that exhibits increased effectiveness in inhibiting the expression of a target gene by means of RNA interference, wherein at least [one] end of the dsRNA comprises a nucleotide overhang of 1 to 4 unpaired nucleotides in length [and] … the unpaired nucleotide adjacent to the terminal nucleotide pair comprises a purine base," the patent's abstract states. Further, "the terminal nucleotide pair on both ends of the dsRNA is a G-C pair, or at least two of the last four consecutive terminal nucleotide pairs are G-C pairs."


Title: Compositions and Methods for Short Interfering Nucleic Acid Inhibition of Na v1.8

Patent Number: 7,786,291

Filed: Oct. 26, 2005

Lead Inventor: Sameer Goregaoker, Schering

"The invention provides short interfering nucleic acids, either single-stranded or double-stranded, that cause RNAi-induced degradation of mRNA from the Nav1.8 sodium channel gene; to pharmaceutical compositions comprising such short interfering nucleic acids; recombinant vectors comprising such short interfering nucleic acids; a method for inhibiting translation of an mRNA; a method for inhibiting expression of a polypeptide; a method for blocking the membrane potential in a cell; a method for blocking the sodium current in a cell; and a method for inhibiting chronic pain," according to the patent's abstract.


Title: Recombinant DNA Constructs [Containing] Engineered Plant microRNAs and Methods for Controlling Gene Expression

Patent Number: 7,786,350

Filed: Oct. 10, 2006

Lead Inventor: Edwards Allen, Monsanto Technology

The invention "provides constructs containing engineered miRNAs or miRNA precursors derived from a maize miR408b, transgenic plant cells, plants, and seeds containing such constructs, and methods for their use," the patent's abstract states.


Title: Amphoteric Liposomes

Patent Number: 7,780,983

Filed: Oct. 31, 2006

Lead Inventor: Steffen Panzer, Novosom (Marina Biotech)

The patent, its abstract states, claims "amphoteric liposomes … [comprising] positive and negative membrane-based or membrane-forming charge carriers, as well as the use of these liposomes."


Title: RNA Antagonist Compounds for the Modulation of PCSK9

Application Number: 20100216864

Filed: Oct. 9, 2007 PCT Filed: Oct. 9, 2007

Lead Inventor: Ellen Marie Straarup, Technical University of Denmark

The invention comprises "compounds, compositions, and methods for modulating the expression of PCSK9," the patent application's abstract states. "In particular, this invention relates to oligomeric compounds, such as oligonucleotide compounds, which are hybridizable with target nucleic acids encoding PCSK9, and methods for the preparation of such oligomeric compounds. The oligonucleotide compounds have been shown to modulate the expression of PCSK9, and pharmaceutical preparations thereof and their use as treatment of hypercholesterolemia and related disorders are disclosed."


Title: microRNA Compositions in the Treatment of VEGF-Mediated Disorders

Application Number: 20100216865

Filed: Sept. 29, 2008 PCT Filed: Sept. 29, 2008

Inventor: Jack Elias

"The invention provides methods of treating diseases caused by the over-production of a VEGF polypeptide by administering miRNA or miRNA inhibitor compositions to decrease at least one activity of a VEGF polypeptide," the patent application's abstract states.


Title: RNAi Modulation of ApoB and Uses Thereof

Application Number: 20100216866

Filed: March 19, 2010

Lead Inventor: Juergen Soutschek, Alnylam Pharmaceuticals

"The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the down-regulation of apolipoprotein B by chemically modified oligonucleotides," according to the patent application's abstract.


Title: Agents, Compositions, and Methods for Treating Pathologies in which Regulating an AChE-Associated Biological Pathway is Beneficial

Application Number: 20100216868

Filed: March 6, 2008 PCT Filed: March 6, 2008

Lead Inventor: Hermona Soreq, Hebrew University of Jerusalem

The invention, the patent application's abstract states, "provides agents which are capable of regulating the function of a microRNA component which can be used to regulate an AChE-associated biological pathway. In addition, the … invention provides methods and pharmaceutical compositions for the treatment of various pathologies related to AChE-associated biological pathways such as apoptosis, aberrant cholinergic signaling, abnormal hematopoietic proliferation and/or differentiation, cellular stress, exposure to inflammatory response-inducing agents, and/or exposure to organophosphates or other AChE inhibitors."


Titles: RNAi Inhibition of Alpha-ENaC Expression

Application Numbers: 20100216971, 20100216972

Filed: April 30, 2010

Lead Inventor: Gino Van Heeke, Novartis

The inventions, the patent applications' abstracts state, relate to "compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the down-regulation of alpha-ENaC expression by chemically modified oligonucleotides."

The Scan

Science Confidence Boost

The New York Times reports that a new poll finds trust in science and scientists has increased with the COVID-19 pandemic.

Appeal and Funds

Some grant applications denied funding due to an Australian Research Council rule change have now been funded following an appeal, the Guardian reports.

Surveillance for Variants

Vox writes that the detection of the Omicron SARS-CoV-2 variant highlights the need for improved viral genomic surveillance.

Nature Papers Examine Taxonomic Gaps in Plant Sequencing, SARS-CoV-2-Human Interactome

In Nature this week: plant genome sequencing dominated by affluent countries, and more.